<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03867357</url>
  </required_header>
  <id_info>
    <org_study_id>1653</org_study_id>
    <nct_id>NCT03867357</nct_id>
  </id_info>
  <brief_title>Intramuscular Mechanisms of Androgen Deprivation-related Sarcopenia</brief_title>
  <official_title>Intramuscular Mechanisms of Androgen Deprivation-related Sarcopenia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Seattle Institute for Biomedical and Clinical Research</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>United States Department of Defense</agency>
      <agency_class>U.S. Fed</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Washington</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Seattle Institute for Biomedical and Clinical Research</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Prostate cancer (PCa) is the most common cancer among men and is even more common in the
      military and veteran population. For patients with advanced prostate cancer, the most common
      treatment includes lowering the levels of the hormone testosterone as much as possible. This
      is called &quot;androgen deprivation therapy&quot; or &quot;ADT&quot;. Unfortunately, ADT also causes patients to
      be fatigued, weak and to loose muscle. This is often referred to as &quot;sarcopenia&quot; and it leads
      to falls, poor quality of life and higher risk of death. Currently, there is no treatment for
      sarcopenia because the investigators do not understand the mechanisms that cause it. The
      mitochondria is the part of the cells responsible for providing energy to muscles but to this
      date the investigators do not know if it is affected in prostate cancer patients with
      sarcopenia due to ADT.

      The overall goal of this proposal is to establish if the mitochondria is responsible for
      sarcopenia in patients with prostate cancer receiving ADT. The investigators will measure
      mitochondrial function, muscle mass and strength, and feelings of fatigue and quality of life
      in patients with prostate cancer before starting and after 6 months of ADT.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Prostate cancer (PCa) is the most common cancer among men. Androgen deprivation therapy (ADT)
      is the standard treatment for advanced and metastatic PCa and nearly 400,000 men remain on
      androgen deprivation therapy (ADT) for advanced PCa in the U.S. Unfortunately, ADT also
      induces a decrease in muscle mass and function, known as sarcopenia, a condition that leads
      to decreased endurance, increased fatigue, falls, poor health-related quality of life
      (HR-QOL) and increased mortality. The mechanisms underlying the development of ADT-induced
      sarcopenia are incompletely understood and remain a significant barrier to the development of
      therapies for this condition. Mitochondria play an essential role in generating the adenosine
      triphosphate (ATP) needed for muscle contraction and abnormalities in mitochondria function
      have been reported in animal models of sarcopenia. The extent to which mitochondrial
      dysfunction mediates ADT-induced sarcopenia and muscle dysfunction is not known.

      The overall goal of this proposal is to establish the role of mitochondrial dysfunction on
      ADT-induced sarcopenia in patients with PCa. The investigators hypothesize that ADT in men
      with PCa will induce mitochondrial dysfunction leading to sarcopenia.

      Improving scientific understanding of the mechanisms underlying sarcopenia following ADT will
      enable investigators to develop new treatments and novel biomarkers for this disease. Given
      that there are no available therapies for sarcopenia, this is clinically very relevant. The
      near-term impact of this proposal will be to elucidate the extent to which mitochondrial
      dysfunction mediates the development of sarcopenia in veterans and non-veterans with prostate
      cancer undergoing ADT, and to evaluate the potential for these measurements at baseline to
      serve as early predictors of disease. The outcomes that will be directly attributed to the
      results of the proposed research include baseline and changes in muscle mass and performance,
      in-vivo and ex-vivo mitochondrial function, and patient reported outcomes (PROs) including
      fatigue and HR-QOL. The investigators expect that these efforts will have a major impact on
      the goal of reducing morbidity associated with prostate cancer, and improving HR-QOL by
      filling the gap in the knowledge of the mechanisms causing ADT-induced sarcopenia in PCa. The
      mechanisms identified in this grant will be the target of future interventional clinical
      trials.

      The proposed project will address one of the PCRP overarching challenges and focus areas:
      &quot;Survivorship including psychosocial impact on the patient&quot;. If the investigators prove the
      hypothesis that mitochondrial dysfunction plays a significant role in the development of
      sarcopenia, fatigue and poor HR-QOL in veterans and non-veterans with prostate cancer, the
      multidisciplinary team that has been assembled will build on these findings and test
      interventions currently undergoing clinical development to target mitochondria dysfunction in
      this population.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 7, 2018</start_date>
  <completion_date type="Anticipated">August 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">August 31, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Lean body mass (LBM) change</measure>
    <time_frame>Baseline to 3 months</time_frame>
    <description>Changes in LBM (kg) measured by X-ray densitometry (DEXA).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Lean body mass (LBM) change</measure>
    <time_frame>Baseline to 6 months</time_frame>
    <description>Changes in LBM (kg) measured by X-ray densitometry (DEXA).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Body composition change</measure>
    <time_frame>Baseline to 6 months</time_frame>
    <description>Lean body mass and fat mass (kg) measured by dual energy x-ray absorptiometry (DEXA)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Muscle strength change</measure>
    <time_frame>Baseline to 6 months</time_frame>
    <description>Hand grip strength (kg)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Muscle strength change</measure>
    <time_frame>Baseline to 6 months</time_frame>
    <description>Stair climb power (seconds)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Aerobic capacity change</measure>
    <time_frame>Baseline to 6 months</time_frame>
    <description>VO2 max</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Daily physical activity change</measure>
    <time_frame>Baseline to 6 months</time_frame>
    <description>Actigraphy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Skeletal muscle mitochondrial function (in vivo)</measure>
    <time_frame>Baseline to 6 months</time_frame>
    <description>Magnetic resonance spectroscopy (MRS)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Skeletal muscle mitochondrial function (ex vivo)</measure>
    <time_frame>Baseline to 6 months</time_frame>
    <description>Oxygen consumption rate (OCR)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality-of-life change</measure>
    <time_frame>Baseline to 6 months</time_frame>
    <description>EORTC Quality of Life Questionnaire (EORTC QLQ-C30)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality-of-life change</measure>
    <time_frame>Baseline to 6 months</time_frame>
    <description>Expanded Prostate Cancer Index Composite (EPIC) questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality-of-life change</measure>
    <time_frame>Baseline to 6 months</time_frame>
    <description>Functional Assessment of Cancer Therapy-Prostate questionnaire</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Degree of androgen deprivation</measure>
    <time_frame>Baseline to 6 months</time_frame>
    <description>Total and free testosterone levels in blood draw samples</description>
  </other_outcome>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Metastatic Prostate Cancer</condition>
  <condition>Androgen Deprivation Therapy</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GnRH agonist</intervention_name>
    <description>Zoladex is a gonadotropin-releasing hormone agonist, or GnRH-A. It is an implant that is injected under the skin (subcutaneously). The implant gradually dissolves and releases the drug over the time between injections. There are two dosages of Zoladex: Zoladex 10.8 mg, which is injected once every 3 months, and Zoladex 3.6 mg, which is injected once a month.</description>
    <other_name>Zoladex, Goserelin</other_name>
  </intervention>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Plasma
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Male Veteran patients presenting with advanced or metastatic PCa eligible for ADT in the
        Urology clinic at the Veterans Affairs Puget Sound Health Care System.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologically, cytologically, or image based documented advanced or metastatic PCa
             initiating ADT with expected continuous treatment for a minimum of 6 months and
             willing/able to provide informed consent.

          -  Willing and able to provide written informed consent prior to screening.

        Exclusion Criteria:

          -  Liver disease (AST or ALT equal or more than 3x normal levels);

          -  Renal failure (creatinine equal or more than 2.5 mg/dL);

          -  Untreated thyroid disease, class III-IV CHF, AIDS;

          -  Other cancer diagnosed within the past five years other than non-melanoma skin cancer;

          -  Severe COPD requiring use of home O2;

          -  Chronic, uncontrolled hypertension as judged by the Investigator (i.e., Baseline SBP
             &gt;150 mm Hg, DBP &gt;90 mm Hg) or a SBP &gt; 150 mm Hg or DBP &gt; 95 mm Hg at the time of
             screening or baseline;

          -  An active, uncontrolled infection or cardiovascular disease including a recent
             myocardial infarction (MI), cerebrovascular accident (CVA), arrhythmias or unstable
             angina (&lt; 6 months);

          -  Uncontrolled diabetes mellitus (as defined by a HbA1c equal or more than 9%);

          -  Underlying muscular or neuromuscular disorder or neurologic deficit contributing to
             sarcopenia;

          -  Enrolled in a clinical trial involving an investigational product or non-approved use
             of a drug/device or concurrently enrolled in medical research not scientifically or
             medically compatible with this study;

          -  Current use (within one month) of testosterone, high dose steroids (20mg of
             prednisone/day for more than 1 month), or megestrol treatment for cancer within the
             previous 3 months;

          -  Previous treatment with ADT other than oral anti-androgen at initiation of ADT;

          -  Metal implants in the right limbs (non-MRI compatible metal stents, titanium
             pins/markers, etc.) or implanted cardiac pacemaker or other implanted non-MRI
             compatible cardiac device (e.g., stent);

          -  A history of vascular problems (DVT, etc.)
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jose M Garcia, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Veterans Affairs Puget Sound Health Care System, University of Washington</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jonathan Lee, BS</last_name>
    <phone>2062775087</phone>
    <phone_ext>65087</phone_ext>
    <email>Jonathan.Lee3@va.gov</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Lindsey Anderson, PhD</last_name>
    <phone>2062776719</phone>
    <phone_ext>66719</phone_ext>
    <email>Lindsey.Anderson5@va.gov</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Veterans Affairs Puget Sound Health Care System</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98108</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jonathan Lee, BS</last_name>
      <phone>206-277-5087</phone>
      <phone_ext>65087</phone_ext>
      <email>Jonathan.Lee3@va.gov</email>
    </contact>
    <contact_backup>
      <last_name>Lindsey Anderson, PhD</last_name>
      <phone>2062776719</phone>
      <phone_ext>66719</phone_ext>
      <email>Lindsey.Anderson5@va.gov</email>
    </contact_backup>
    <investigator>
      <last_name>Jose M Garcia, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Shanely RA, Zwetsloot KA, Triplett NT, Meaney MP, Farris GE, Nieman DC. Human skeletal muscle biopsy procedures using the modified Bergstr√∂m technique. J Vis Exp. 2014 Sep 10;(91):51812. doi: 10.3791/51812.</citation>
    <PMID>25285722</PMID>
  </reference>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>February 26, 2019</study_first_submitted>
  <study_first_submitted_qc>March 5, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">March 8, 2019</study_first_posted>
  <last_update_submitted>April 28, 2020</last_update_submitted>
  <last_update_submitted_qc>April 28, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 30, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Androgen deprivation therapy</keyword>
  <keyword>Prostate cancer</keyword>
  <keyword>Sarcopenia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
    <mesh_term>Sarcopenia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Goserelin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>January 17, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/57/NCT03867357/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

